Navigation Links
Management of ascites, spontaneous bacterial peritonitis, and hepatorenal syndrome in cirrhosis
Date:8/2/2010

The peer reviewed guidelines will be available in the September 2010 issue, (Volume 53, No.3) of the Journal of Hepatology and online in advance of publication at http://www.ncbi.nlm.nih.gov/pubmed/20633946 . They also provide recommendations for the management of spontaneous bacterial peritonitis (SBP) and hepatorenal syndrome, which often affect patients with cirrhosis .

An estimated 75 percent of patients presenting with ascites in Western Europe and the USA have cirrhosis as the underlying cause. The development of ascites is an extremely common yet debilitating complication for cirrhotic patients and has a huge impact on their life expectancy and quality of life. SBP and hepatorenal syndrome are ominous complications of which patients with ascites are at risk. They carry a high mortality and prophylactic measures, early diagnosis and appropriate treatments are crucial, especially to bridge eligible patients to liver transplantation.

"It is estimated that almost 60 percent of cirrhotic patients develop ascites within 10 years of their disease, which is a huge proportion of patients. These guidelines provide clinicians with the latest recommendations from a panel of experts on the management of ascites, SBP and hepatorenal syndrome. It is hoped that the guidelines will improve and facilitate best practice and ultimately improve disease outcomes and symptoms for cirrhotic patients in the future," stated Pere Gins, lead contributor of the guidelines.

These guidelines aim to assist clinicians in the decision making and management process for ascites, SBP and hepatorenal syndrome, as well as inform patients and their carers of optimal treatment and care. New and updated best practice for the screening, diagnosis and management of these conditions are offered, with particular emphasis on:

  • Prevalence and prognosis of ascites
  • Management of the various stages of its development
  • Diagnostic strategies for ascites, SBP and hepatorenal syndrome
  • The use of drugs, antibiotics and diuretics and their associated complications
  • Ascitic fluid analysis for assessing peritoneal infections
  • Methods to improve renal function and considerations of liver transplantation

"EASL is dedicated to promoting research and education in the field of hepatology to improve the treatment of liver disease throughout the world. Its series of clinical practice guidelines aims to promote best practise to drive better clinical outcomes and inform both the scientific community and the wider public of the latest developments in the field. We hope these new ascites guidelines provide clinicians with the most up-to-date, evidence based methods for the management of patients affected by this common and debilitating disease" added Professor Heiner Wedemeyer, EASL Secretary General.


'/>"/>

Contact: Dimple Natali
dimple.natali@cohnwolfe.com
44-207-331-5381
European Association for the Study of the Liver
Source:Eurekalert

Related biology news :

1. Case Western Reserve University project ties soil conservation and river management together
2. Almond pest management team to receive major award at ESA meeting
3. First-ever socioeconomic study on coral reefs points to challenges of coastal resource management
4. Understanding phosphorus in soils is vital to proper management
5. Preventing rangeland erosion: Developing better management practices in Iran
6. Long-term study of orchard ground cover management systems
7. Organizational Change Management for Sustainability: The Harvard Case Study
8. Ecological insect pest management for Guam
9. Research synthesis shines light on several management options after fires in diverse ecosystems
10. Pest management specialist Charles Summers wins prestigious Woodworth Award
11. Public trust doctrine could aid management of US oceans
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/12/2016)... , May 12, 2016 WearablesResearch.com ... just published the overview results from the Q1 wave ... the recent wave was consumers, receptivity to a program ... data with a health insurance company. "We ... to share," says Michael LaColla , CEO of ...
(Date:4/28/2016)... April 28, 2016 First quarter 2016:   ... 966% compared with the first quarter of 2015 The ... 589.1 M (loss: 18.8) and the operating margin was 40% (-13) ... Cash flow from operations was SEK 249.9 M (21.2) ... guidance is unchanged, SEK 7,000-8,500 M. The operating margin ...
(Date:4/15/2016)... 2016  A new partnership announced today will ... decisions in a fraction of the time it ... high-value life insurance policies to consumers without requiring ... Force Diagnostics, rapid testing (A1C, Cotinine and HIV) ... pressure, weight, pulse, BMI, and activity data) available ...
Breaking Biology News(10 mins):
(Date:6/23/2016)... - FACIT has announced the creation of a ... Propellon Therapeutics Inc. ("Propellon" or "the Company"), to ... of first-in-class WDR5 inhibitors for the treatment of ... an exciting class of therapies, possessing the potential ... patients. Substantial advances have been achieved with the ...
(Date:6/23/2016)... June, 23, 2016  The Biodesign Challenge (BDC), a ... ways to harness living systems and biotechnology, announced its ... in New York City . ... students, showcased projects at MoMA,s Celeste Bartos Theater during ... , MoMA,s senior curator of architecture and design, and ...
(Date:6/23/2016)... June 23, 2016 Apellis Pharmaceuticals, Inc. ... clinical trials of its complement C3 inhibitor, APL-2. ... multiple ascending dose studies designed to assess the ... subcutaneous injection in healthy adult volunteers. ... as a single dose (ranging from 45 to ...
(Date:6/23/2016)... ... June 23, 2016 , ... Regulatory Compliance ... consulting, provides a free webinar on Performing Quality Investigations: Getting to ... 12pm CT at no charge. , Incomplete investigations are still a major concern ...
Breaking Biology Technology: